Eventide Asset Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Eventide Asset Management’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-393,000	Closed	-$8.02M	–	138
2016 Q1	$8.02M	Sell	393,000 -82,800	-17%	-$2.63M	0.45%	60
2015 Q4	$24.5M	Sell	475,800 -4,100	-0.9%	-$199K	1.22%	35
2015 Q3	$20.5M	Buy	479,900 +74,600	+18%	+$3.6M	1.19%	32
2015 Q2	$18.5M	Hold	405,300	–	–	1%	43
2015 Q1	$15.4M	Buy	405,300 +32,900	+9%	+$1.13M	1.16%	38
2014 Q4	$10.5M	Hold	372,400	–	–	1.15%	36
2014 Q3	$9.41M	Hold	372,400	–	–	1.31%	32
2014 Q2	$10.9M	Buy	372,400 +8,900	+2%	+$215K	1.48%	28
2014 Q1	$9.41M	Buy	363,500 +190,200	+110%	+$5.08M	1.46%	30
2013 Q4	$4.46M	Buy	+173,300	New	+$4.21M	1.37%	38

Other funds holding PTLA

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Eventide Asset Management's PTLA Position: Q2 2016 in Review

Eventide Asset Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2016, closing a stake of 393,000 shares — an estimated $8.02M sold.

Eventide Asset Management first reported a position in PTLA in Q4 2013 and held it in 10 quarters. The position peaked at $24.5M in Q4 2015. 159 funds tracked by Wall St. Rank hold PTLA as of Q2 2016.

Eventide Asset Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
Eventide Asset Management sold 393,000 Portola Pharmaceuticals, Inc. shares in Q2 2016, an estimated $8.02M.
Eventide Asset Management first reported a position in Portola Pharmaceuticals, Inc. in Q4 2013 and held it in 10 quarters.
Eventide Asset Management's Portola Pharmaceuticals, Inc. position peaked at $24.5M in Q4 2015.
159 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2016.

Based on Eventide Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.